Prothena Appoints New CMO, Dr. Cox Departs
Ticker: PRTA · Form: 8-K · Filed: Dec 12, 2025 · CIK: 1559053
| Field | Detail |
|---|---|
| Company | Prothena Corp Public Ltd Co (PRTA) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel
TL;DR
Prothena's CMO is out, new one in. Watch compensation details.
AI Summary
Prothena Corporation plc announced on December 10, 2025, the departure of Dr. Genevieve L. Cox from her role as Chief Medical Officer. Concurrently, the company appointed Dr. Sarah L. Galvin as the new Chief Medical Officer. Dr. Galvin's compensation arrangements are detailed in this filing.
Why It Matters
Changes in key executive positions, especially the Chief Medical Officer, can signal shifts in a company's strategic direction and pipeline development, potentially impacting investor confidence and future research outcomes.
Risk Assessment
Risk Level: medium — Executive departures and appointments, particularly in critical roles like CMO, can introduce uncertainty regarding leadership stability and strategic continuity.
Key Players & Entities
- Prothena Corporation plc (company) — Registrant
- Dr. Genevieve L. Cox (person) — Departing Chief Medical Officer
- Dr. Sarah L. Galvin (person) — Appointed Chief Medical Officer
- December 10, 2025 (date) — Date of earliest event reported
FAQ
Who is the new Chief Medical Officer at Prothena Corporation plc?
Dr. Sarah L. Galvin has been appointed as the new Chief Medical Officer.
Who has departed from Prothena Corporation plc's executive team?
Dr. Genevieve L. Cox has departed from her role as Chief Medical Officer.
What is the effective date of the reported events?
The earliest event reported is dated December 10, 2025.
What specific items are being reported in this 8-K filing?
The filing reports the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What is Prothena Corporation plc's SIC code?
Prothena Corporation plc's Standard Industrial Classification (SIC) code is 2834, for Pharmaceutical Preparations.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-12-12 16:26:08
Key Financial Figures
- $0.01 — Registered Ordinary Shares, par value $0.01 per share PRTA The Nasdaq Global Select
Filing Documents
- prta-20251210.htm (8-K) — 29KB
- 0001559053-25-000049.txt ( ) — 149KB
- prta-20251210.xsd (EX-101.SCH) — 2KB
- prta-20251210_lab.xml (EX-101.LAB) — 23KB
- prta-20251210_pre.xml (EX-101.PRE) — 13KB
- prta-20251210_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 12, 2025 PROTHENA CORPORATION PLC By: /s/ Tran B. Nguyen Name: Tran B. Nguyen Title: Chief Strategy Officer and Chief Financial Officer